相关实验视频

Updated: Jul 3, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

肺腺癌中PI3K/Akt/mTOR途径相关 lncRNAs的识别和功能性表征:一项回顾性研究

Jiaqi Zhong¹, Ying Kong², Ruming Li¹

¹The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, China.

|February 14, 2024

概括

研究人员确定了七种与PI3K/Akt/mTOR途径相关的长非编码RNA (lncRNA),有助于肺腺癌 (LUAD) 的预后预测和免疫治疗优化. 这一发现增强了对LUAD免疫微环境的理解.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物信息学是一种生物信息学.

背景情况:

肺腺癌 (LUAD) 是癌症死亡的主要原因.
免疫疗法在治疗LUAD方面表现有前途,但患者选择仍然是一个挑战.
PI3K/Akt/mTOR信号通路在LUAD的发展和进展中起着至关重要的作用.

研究的目的:

为了识别与LUAD中的PI3K/Akt/mTOR通路调节器相关的长非编码RNA (lncRNA) 签名.
为接受免疫治疗的LUAD患者开发预后模型.
探索这些lncRNAs,免疫微环境和治疗反应之间的关联.

主要方法:

使用单变量和多变量考克斯回归和LASSO回归的回顾性分析.
鉴定与预后相关的 lncRNA 和预后模型的构建.
基因本体学 (GO) 和KEGG通路分析,随后进行免疫检测和药物查.
使用Imvigor210队列的验证和瘤干细胞的分析.

主要成果:

确定了七个与预后相关的lncRNAs (AC084757.3,AC010999.2,LINC02802,AC026979.2,AC024896.1,LINC00941,LINC01312).这些 lncRNAs中,有7个是与预后相关的.
开发了预后模型,以预测LUAD患者的存活率.
凯格分析证实了LUAD与PI3K/Akt/mTOR通路的关联;确定了三个有利的免疫通路.
使用pRRophetic算法选了73种化疗药物.

结论:

已识别的七个lncRNA为预测LUAD预后提供了宝贵的见解.
这些lncRNAs有助于理解LUAD中的免疫微环境.
这些发现可以帮助优化LUAD患者的免疫疗法策略.

关键词:

免疫治疗是一种免疫疗法.肺部腺癌是肺部腺癌.预测预后预测预测瘤微环境是一个微环境.在 lncRNAs 中.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...